BRAF Inhibitor Treatment Causes Melanoma Cells to Shift How They Produce Energy, Massachusetts General Hospital Study

Published: Mar 11, 2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

Back to news